MGMichael de Graaf

Michael de Graaf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael de Graaf has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • André Gerardus Uitterlinden

    Erasmus Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands

    1 shared publication
  • Annemieke Johanna Maria Henriëtta Verkerk

    Erasmus Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands

    1 shared publication
  • Egbert Johan Willem Redeker

    Academic Medical Center, Department of Clinical Genetics, Amsterdam, The Netherlands

    1 shared publication
  • Gijs Willem Eduard Santen

    Leiden University Medical Center, Department of Clinical Genetics, Leiden, The Netherlands

    1 shared publication
  • Jan Maarten Wit

    Leiden University Medical Center, Department of Pediatrics, Leiden, the Netherlands

    1 shared publication
  • Monique Losekoot

    Leiden University Medical Center, Department of Clinical Genetics, Leiden, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Successful Growth Hormone Therapy in Cornelia de Lange Syndrome

    by Michael de Graaf, Sarina G Kant, Jan Maarten Wit, Egbert Johan Willem Redeker, Gijs Willem Eduard Santen, Annemieke Johanna Maria Henriëtta Verkerk, André Gerardus Uitterlinden, Monique Losekoot, Wilma Oostdijk

    Cornelia de Lange syndrome (CdLS) is a both clinically and genetically heterogeneous syndrome. In its classical form, it is characterised by distinctive facial features, intra-uterine growth retardation, short stature, developmental delay, and anomalies in multiple organ systems. NIPBL, SMC1A, SMC3, RAD21 and HDAC8, all involved in the cohesin pathway, have been identified to cause CdLS. Growth hormone (GH) secretion has been reported as normal, and to our knowledge, there are no reports on the effect of recombinant human GH treatment in CdLS patients. We present a patient born small for gestational age with persistent severe growth retardation [height -3.4 standard deviation score (SDS)] and mild dysmorphic features, who was treated with GH from 4.3 years of age onward and was diagnosed 6 years later with CdLS using whole-exome sequencing. Treatment led to a height gain of 1.6 SDS over 8 years. Treatment was interrupted shortly due to high serum insulin-like growth factor-1 serum values. In conclusion, GH therapy may be effective and safe for short children with CdLS.